Evidence for downregulation of calcium signaling proteins in advanced mouse adenocarcinoma

Prostate

Volumn 64, Issue 2, 2005, Pages 128-138

  Ruddat, Viola C ^a   Whitman, Stephanie ^a   Klein, Russell D ^b   Fischer, Susan M ^c   Holman, Theodore R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Calcium regulating proteins; Prostate cancer; Proteomics

Indexed keywords

BETA TUBULIN; CALRETICULIN; CREATINE KINASE BB; CYCLINE; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70;

ADVANCED CANCER; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIUM SIGNALING; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN DETERMINATION; PROTEOMICS; TRANSGENIC MOUSE; TUMOR DIFFERENTIATION; WESTERN BLOTTING; WILD TYPE;

ADENOCARCINOMA; ANIMALS; CALCIUM SIGNALING; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; MALE; MICE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; PROTEINS; PROTEOMICS;

EID: 20344389505     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20207     Document Type: Article

References (64)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. Cancer J Clin 2001;51:15-36.
2. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, Patel A, Richie JP, Walsh PC, Scardino PT. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology 2000;56(2):255-260.
3. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery-What we have learned and where we are going. J Urol 1999;162(2):293-306.
4. Watson RW, Schalken JA. Future opportunities for the diagnosis and treatment of prostate cancer. Prostate Cancer Prostatic Dis 2004;7 (Suppl 1):S8-S13.
5. Gingrich RJ, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-4691.
6. Schmidt JD. The case for early endocrine treatment of advanced or metastatic prostate cancer. Prostate 1996;28(3):201-204.
7. Lepor H, Ross A, Walsh PC. The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 1982; 128(2):335-340.
8. Kramolowsky EV. The value of testosterone deprivation in stage D1 carcinoma of the prostate. J Urol 1988;139(6):1242-1244.
9. Abel PD, Lani EN. Prostate cancer: Clinical and scientific aspects - Bridging the gap. London: Imperial College Press, 2003.
10. Raffo AJ, Perlman MW, Chen M, Day JS, Steitman R. Overexpression of Bcl-2 protects cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.
11. Fixemer T, Remberger K, Bonkhoff H. Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002;53:118-123.
12. McConkey D, Orrenius S. The role of calcium in the regulation of apoptosis. Biochem Biophys Res Commun 1997;239:357-366.
13. Furuya Y. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cells induced by thapsigargin. Cancer Res 1994; 54(23):6167-6175.
14. Martikainen P, Kyprianou N, Tucker R, Isaacs J. Programmed death of nonproliferating androgen-independent prostatic cancer cells. Cancer Res 1991;51:4693-4700.
15. Petranka J, Wright G, Forbes R, Murphy E. Elevated calcium in preneoplastic cells activates NF-kB and confers resistance to apoptosis. J Biol Chem 2001;276(40):37102-37108.
16. 2+ homeostasis and apoptotic resistance of neuroendocrine-differentiated prostate cancer cells. Cell Death Differ 2004;11(3):321-330.
17. Kyprianou N, Martikainene P, Davis L, English H, Isaacs J. Programmed cell death as a new target for prostatic cancer therapy. Cancer Survival 1991;11:265-277.
18. 2+ entry. Cancer Res 2000;15:1002-1008.
19. + channel gating. Mol Pharmacol 2001;59:1376-1387.
20. ++-binding protein abundantly expressed and regulated by androgen in prostatic epithelial cells. Endocrinology 1998;139(10):4337- 4344.
21. Batra S, Popper L, Hartley-Asp B. The effect of calcium antagonists on Ca influx and cellular growth of human prostatic tumor cells. Prostate 1991;19:299-311.
22. Zhu N, Wang Z. Calreticulin expression is associated with androgen regulation of the sensitivity to calcium ionohore-induced apoptosis in LNCaP prostate cancer cells. Cancer Res 1999;59:1896-1902.
23. Adam BL, Viahou A, Semmes OJ, Wright GL. Proteomic approach to biomarker discovery in prostate and bladder cancers. Proteomics 2001;1:1264-1270.
24. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92(8):3439-3443.
25. Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J, et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001;1:377-396.
26. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, Lewis S, et al. A novel experimental design for comparative two-dimensional gel analysis: Two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3:36-44.
27. Haese A, Hartwig H, Recker F, Kwiatkowski M. Staging of prostate cancer based on human glandular kallikrein 2 levels. PCT Int Appl 2000; WO 2000050899.
28. Ahram M, Best CJM, Flaig MJ, Gillespie JW, Leiva IM, Chuaqi RF, et al. Proteomic analysis of human prostate cancer. Mol Carcinog 2002;33:9-15.
29. Delescluse C, Furstenberger G, Marks F, Prunieras M. Effects of phorbol esters on basal epidermal cells derived from ear skin of adult guinea pigs. Cancer Res 1982;42(5):1975-1979.
30. Pollard M, Luckert PH. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone. J Natl Cancer Inst 1986;77(2): 583-587.
31. LeRoy BE, Bahnson RR, Rosol TJ. Canine prostate induces new bone formation in mouse calvaria: A model of osteoinduction by prostate tissue. Prostate 2002;50(2):104-111.
32. Gingrich RJ, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, et al. Metastic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
33. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55(3):219-237.
34. Shappell SB, Thomas GV, Roberts RL, Herbert R, Ittmann MM, Rubin MA, et al. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004; 64(6):2270-2305.
35. Uchida K, Masumori N, Takahashi A, Itoh N, Tsukamoto T. Characterization of prostatic neuroendocrine cell line established from neuroendocrine carcinoma of transgenic mouse allograft model. Prostate 2005;62:40.
36. Wong YC, Tam NN. Dedifferentiation of stromal smooth muscle as a factor in prostate carcinogenesis. Anticancer Res 2003; 23(2B):1325-1331.
37. Alaiya A, Roblick U, Egevad L, Carlsson A. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol 2000;21:1-9.
38. Bichsel VE, Liotta LA, Petricoin EF. Cancer proteomics: from biomarker discovery to signal pathway profiling. Cancer J 2001;7:69-78.
39. Ayala G, Tuxhorn JA, Wheeler TM, Frolov A, Scardino PT, Ohori M, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003;9(13):4792-4801.
40. Jaskulski D, deRiel JK, Mercer WE, Calabretta B, Baserga R. Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNA cyclin. Science 1988;240(4858):1544-1546.
41. Bravo R, Frank R, Blundell PA, Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 1987;326(6112):515-517.
42. Burns RG, Farrell KW. Getting to the heart of beta-tubulin. Trends Cell Biol 1996;6(8):297-303.
43. Harper ME, Glynne-Jones E, Goddard L, Wilson DW, Matenhelia SS, Conn IG, Peeling WB, Griffiths K. Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters. The Prostate 1992;20(3):243-253.
44. Alaiya AO, Langridge J, Rolick U, Egevad L, Braenstedt S, Hellstroem M, et al. Identification of proteins in human prostate tumor material by two-dimensional gel electrophoresis and mass spectrometry. Cell Mol Life Sci 2001;(58):307-311.
45. Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099-7105.
46. Anelli T, Alessio M, Mezghrani A, Simmen T, Talamo F, Bachi A, et al. ERp44, a novel endoplasmic reticulum folding assistant of the thioredoxin family. EMBO J 2002;21(4):835-844.
47. Jäättelä M. Escaping cell death: Survival proteins in cancer. Exp Cell Res 1999;248:30-43.
48. Feld RD, Van Steirteghem AC, Zweig MH, Weimar GW, Narayana AS, Witte DL. The presence of creatine kinase BB isoenzyme in patients with prostatic cancer. Clin Chim Acta 1980;100(3):267-273.
49. Zarghami N, Yu H, Diamandis EP, Sutherland DJA. Quantification of creatine kinase BB isoenzyme in tumor cytosols and serum with an ultrasensitive time-resolved immunofluorometric technique. Clin Biochem 1995;28(3):243-253.
50. Nagano K, Masters JR, Akpan A, Yang A, Corless S, Wood C, et al. Differential protein synthesis and expression levels in normal and neoplastic human prostate cells and their regulation by type I and II interferons. Oncogene 2004;23:1693-1703.
51. Prasad SC, Soldatenkov VA, Kuettel MR, Thraves PJ, Zou X, Drischilo A. Protein changes associated with ionizing radiation-induced apoptosis in human prostate epithelial tumor cells. Electrophoresis 1999;(20):1065-1074.
52. Krause KH, Michalak M. Calreticulin. Cell 1997;88:439-443.
53. Bruchovsky N, Lesser B, Doom EV, Craven S. Hormonal effects on cell proliferation in rat prostate. Vitam Horm 1975;33:61-102.
54. Wang Z, Brown DD. A gene expression screen. Proc Natl Acad Sci USA 1991;88:11505-11509.
55. Sriram M, Osipiuk J, Freeman BC, Morimoto RI, Joachimiak A. Human Hsp70 molecular chaperone binds two calcium ions with int ATPase domain. Structure 1997;5:403-414.
56. Jaatela M, Wissing D. Heat shock proteins protect cells from monocyte cytoxicity: Possible mechanism of self-protection. J Exp Med 1993;177:231-236.
57. Wallimann T, Dolder M, Schlattner U, Eder M, Hornemann T, O'Gorman E, et al. Some new aspects of creatine kinase (CK): Compartmentation, structure, function, and regulation for cellular and mitochondrial bioenergetics and physiology. Biofactors 1998;8(3-4):229-234.
58. Wong SS, Wu AHB, Fritsche HA. Assessment of creatine kinase bb as a marker for cancer of the prostate. Clin Chem 1987;33: 809-811.
59. Wang Z, Xiao W. Method for prognostic cancer and the proteins involved. US 2003/0039970 2003.
60. Nylansted J, Brand K, Jäätela M. Heat shock protein 70 is required for the survival of cancer cells. Ann NY Acad Sci 2000: 122-125.
61. Leung DW, Tompkins C, Brewer J, Ball A, Coon M, Morris V, et al. Phospholipase C delta-4 overexpression upregulates ErbB1/2 expression, Erk signaling pathway, and proliferation in MCF-7 cells. Mol Cancer 2004;3(1):15.
62. Manos EJ, Kim ML, Kassis J, Chang PY, Wells A, Jones DA. Dolichol-phosphate-mannose-3 (DPM3)/prostin-1 is a novel phospholipase C-gamma regulated gene negatively associated with prostate tumor invasion. Oncogene 2001;20(22):2781-2790.
63. Berridge MJ. Elementary and global aspects of calcium signalling. J Physiol 1997;499(Pt 2):291-306.
64. Rothermund C, Kondrikov D, Lin M-F, Vishwanatha J. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer. Prostate Cancer Prostatic Diseases 2002;5:236-245.